Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients
This study has been completed.
Azienda Ospedaliera San Giovanni Battista
University of Turin, Italy
Information provided by (Responsible Party):
Paolo Zola, Azienda Ospedaliera San Giovanni Battista
First received: July 5, 2011
Last updated: January 30, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2008|
|Primary Completion Date:||No date given|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Surbone A, Fuso L, Passera R, Ferrero A, Marchese C, Martino C, Luchin A, Di Renzo MF, Zola P. Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications. BMC Res Notes. 2012 Sep 23;5:517. doi: 10.1186/1756-0500-5-517.